Skip to main content

Fischesser Ryan's Form 4 filing

Caribou Biosciences, Inc. (CRBU) · filed Dec 21, 2021

Accession no.
0001209191-21-070797
Filed
Dec 21, 2021
Trade date
Dec 20, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $3.06K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fischesser RyanCIK 0001871155Officer (VP of Finance and Controller)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 20, 2021Common StockPPurchaseAcquired+1,136$2.69F2+$3,055.84101,695Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 20, 2021Common StockXIn-the-money exerciseDisposed−1,136$0.00$07,384Direct
Dec 20, 2021Common StockAGrant or awardAcquired+40,000$0.00$040,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)